A Clinicopathologic Study of Resected Cases of Adenosquamous Carcinoma of the Lung

Shimizu, Junzo; Oda, Makoto; Hayashi, Yoshinobu; Nonomura, Akitaka; Watanabe, Yoh

doi:10.1378/chest.109.4.989

Cited by 59 publications

(67 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The incidence of adenosquamous carcinoma was 8% in our series, which is slightly higher than in previous reports. [1][2][3][4]20) The discrepancy is probably not significant because the reported incidence of adenosquamous carcinoma depends on the diagnostic criteria.…”

Section: Discussionmentioning

confidence: 99%

“…1,2) Some clinicopathological studies have suggested that adenosquamous carcinoma of the lung is more aggressive than adenocarcinoma or squamous cell carcinoma. [2][3][4] However, adenosquamous carcinoma has not been investigated genetically to clarify its histogenesis. On the basis of histology, there are many possibilities, including adenocarcinoma with squamous metaplasia, collision tumor, and bipotential undifferentiated cell origin.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Clonal Analysis of Adenosquamous Carcinoma of the Lung

Niho

Yokose

Kodama

et al. 1999

Japanese Journal of Cancer Research

View full text Add to dashboard Cite

Adenosquamous carcinoma of the lung is a subset of pulmonary carcinomas, and comprises less than 4% of lung carcinomas. Its histogenesis remains unclear. The clonality of adenosquamous carcinoma from four female patients was analyzed to determine whether the clonality between the squamous cell and adenocarcinomatous components coincides. Each lesion was precisely microdissected from methanol-fixed sections. Adjacent normal lung tissue was collected as a normal control. DNA was extracted for clonal analysis based on an X-chromosome-linked polymorphic marker, the human androgen receptor gene (HUMARA). HUMARA was found to be amplified with or without previous digestion by the methylation-sensitive restriction endonuclease HpaII. All four cases were informative. Squamous cell and adenocarcinomatous components showed identical monoclonal patterns in all four patients. In one case, only the squamous cell carcinomatous component showed loss of heterozygosity of the HUMARA locus. The results suggest that the squamous cell and adenocarcinomatous components originate from the same cell.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Clonal Analysis of Adenosquamous Carcinoma of the Lung

Niho

Yokose

Kodama

et al. 1999

Japanese Journal of Cancer Research

View full text Add to dashboard Cite

show abstract

“…Lung adenosquamous cancer (ASC) is a subtype of non-small cell lung cancer (NSCLC) that accounts for between 0.4 and 4% of all lung malignancies (3)(4)(5). ASC is defined as a carcinoma containing squamous cell carcinoma (SCC) and adenocarcinoma (ADC) components with each comprising ≥10% of the total tumor (6).…”

Section: Introductionmentioning

confidence: 99%

Prognostic value of combined platelet, fibrinogen, neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in patients with lung adenosquamous cancer

et al. 2017

View full text Add to dashboard Cite

Abstract. The aim of the present study was to investigate the prognostic value of the combined platelet (PLT), fibrinogen (FBG), neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) (CO-NPF) for postoperative outcomes in patients with lung adenosquamous cancer (ASC). Test results from patients who presented at The Cancer Institute and Hospital of Tianjin Medical University between January 2005 and December 2013 were retrospectively reviewed. CO-NPF was scored between 0 and 4 according to increased PLT, FBG, NLR and PLR prior to being split into two groups based on the presence (≥2) or absence (<2) of the combination of increased inflammatory indexes. In total, data from 134 patients with ASC were reviewed for the present study. Multivariate analysis identified that increased CO-NPF (P= 0.001 and P<0.001, respectively), PLR (P=0.011 and P=0.001, respectively) and FBG (P=0.001 and P<0.001, respectively) were independently associated with shorter disease-free survival (DFS) and overall survival (OS). NLR (P=0.006) and PLT (P=0.001) were independent prognostic factors for OS. The area under the receiver operating characteristic curves of CO-NPF (area under the curve, 0.652, P= 0.008, 95% confidence interval, 0.551-0.752) was increased compared with NLR, PLR, PLT and FBG individually, suggesting that CO-NPF has greater predictive value. CO-NPF was significantly and independently associated with shorter DFS and OS, and had greater predictive value compared with NLR, PLR, PLT and FBG in patients with ASC who underwent surgery.

show abstract

“…The majority of available studies report an aggressive biological behavior of ASCLC (2)(3)(4)(5). In ASCLC, EGFR mutations appear to be important predictive markers for the response to EGFR-tyrosine kinase inhibitors (TKIs), similar to the observed favorable outcome in other cell types of NSCLC (10).…”

Section: Discussionmentioning

confidence: 99%

“…Due to its rarity, ASCLC has not received significant attention in terms of its clinical aspects, with only a limited number of studies investigating the aggressive biological characteristics of ASCLC (2)(3)(4)(5).…”

Section: Introductionmentioning

confidence: 99%

Successful pemetrexed-containing chemotherapy for epidermal growth factor receptor mutation-positive adenosquamous cell carcinoma of the lung: A case report

Watanabe

Tamura

Kagohashi

et al. 2016

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Pemetrexed-containing chemotherapy has shown promise in the treatment of non-small-cell lung cancer (NSCLC). However, although adenosquamous cell lung cancer (ASCLC) is a type of NSCLC, the availability of studies investigating its response to pemetrexed-containing chemotherapy is limited. A 66-year-old woman was referred to Mito Medical Center, University of Tsukuba with hemoptysis and a chest computed tomography (CT) scan revealed a large cavitary mass in the lower lobe of the left lung. The patient underwent left lower lobectomy and mediastinal lymph node dissection. The tumor was staged as pT2bN2M0. An epidermal growth factor receptor (EGFR) exon 19 deletion was identified in the adenocarcinomatous as well as the squamous cell carcinomatous components. Despite gefitinib therapy for pulmonary metastases, the patient developed cavitary metastases in both lungs. Therefore, treatment with pemetrexed-containing chemotherapy was initiated. A chest CT scan revealed significant regression of the metastatic lesions in both lungs, with thinning of the walls. The patient remains well and recurrence-free 19 months after the initiation of pemetrexed-containing chemotherapy. Therefore, the clinical response of EGFR mutation-positive ASCLC to pemetrexed-containing chemotherapy was promising, suggesting pemetrexed to be one of the key drugs for this subset of ASCLC patients.

show abstract

A Clinicopathologic Study of Resected Cases of Adenosquamous Carcinoma of the Lung

Cited by 59 publications

References 9 publications

Clonal Analysis of Adenosquamous Carcinoma of the Lung

Clonal Analysis of Adenosquamous Carcinoma of the Lung

Prognostic value of combined platelet, fibrinogen, neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in patients with lung adenosquamous cancer

Successful pemetrexed-containing chemotherapy for epidermal growth factor receptor mutation-positive adenosquamous cell carcinoma of the lung: A case report

Contact Info

Product

Resources

About